ArticleFrontiers in oncology2021

Targeting the MDSCs of Tumors In Situ With Inhibitors of the MAPK Signaling Pathway to Promote Tumor Regression.

Jiayun Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.